Skip to main content

Advertisement

SpringerLink
Log in

Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

Overactive bladder (OAB) is a syndrome with symptoms such as urinary frequency, urinary urgency and urge incontinence. The aim of this study is to assess the validity and reliability of the Turkish overactive bladder symptom score (OABSS) and to evaluate the results of mirabegron treatment with OABSS.

Methods

The study was carried out with 117 patients who applied to the urology outpatient clinic between June 2018–January 2019. OABSS Turkish validation was developed from the English version. Demographic data of the patients were recorded. The OABSS, overactive bladder questionnaire (OAB-v8) and International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) were filled out by the patients. The patients were asked to fill in these questionnaires after 2 weeks. Patients receiving mirabegon treatment were evaluated with the same questionnaires and bladder diaries after 8 weeks.

Results

A total of 117 OAB patients, including 82 OAB-wet and 35-OAB dry, were included in the study. The mean age of the patients was 46.79 ± 14.26 (18–78) years, and the mean duration of OAB complaint was 32.28 ± 32.21 months. The mean score of the OABSS is 9.9 ± 3.14. The results of the reliability assessment showed that the intraclass correlation coefficient of the total OABSS score was 0.71 (weighted coefficients of individual item points, 0.635–0.831), and the Cronbach α was 0.736. In the validity analysis, the OABSS total score was highly correlated with that belonging to other questionnaire forms (OAB-v8, ICIQ-SF and bladder diary). After the treatment with mirabegron, mean OABSS scores of the patients improved significantly from baseline to the 8th week (p < 0.001).

Conclusion

The Turkish version of the OABSS has been approved as a valid and reliable tool for evaluating OAB. Mirabegron used daily improved the symptoms of OAB in patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.

    Article  PubMed  Google Scholar 

  2. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res: Int J Qual Life Aspects Treat Care Rehab. 2002;11(6):563–74.

    Article  CAS  Google Scholar 

  3. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–90.

    CAS  PubMed  Google Scholar 

  4. Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009;56(1):14–20. https://doi.org/10.1016/j.eururo.2009.02.026.

    Article  PubMed  Google Scholar 

  5. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. https://doi.org/10.1007/s00345-002-0301-4.

    Article  CAS  PubMed  Google Scholar 

  6. Zumrutbas AE, Bozkurt AI, Tas E, Acar CI, Alkis O, Coban K, et al. Prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in western Turkey: results of a population-based survey. Int J Urol : Off J Jap Urol Assoc. 2014;21(10):1027–33. https://doi.org/10.1111/iju.12519.

    Article  Google Scholar 

  7. Bradley CS, Rahn DD, Nygaard IE, Barber MD, Nager CW, Kenton KS, et al. The questionnaire for urinary incontinence diagnosis (QUID): validity and responsiveness to change in women undergoing non-surgical therapies for treatment of stress predominant urinary incontinence. Neurourol Urodyn. 2010;29(5):727–34. https://doi.org/10.1002/nau.20818.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology. 2006;68(2 Suppl):9–16. https://doi.org/10.1016/j.urology.2006.05.042.

    Article  PubMed  Google Scholar 

  9. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322–30. https://doi.org/10.1002/nau.20041.

    Article  PubMed  Google Scholar 

  10. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189(1):98–101.

    Article  PubMed  Google Scholar 

  11. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9. https://doi.org/10.1016/j.jclinepi.2007.03.012.

    Article  PubMed  Google Scholar 

  12. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology. 2006;68(2):318–23. https://doi.org/10.1016/j.urology.2006.02.042.

    Article  PubMed  Google Scholar 

  13. Homma Y, Fujimura T. Psychometric validation of the English version of the overactive bladder symptom score. Urology. 2014;84(1):46–50. https://doi.org/10.1016/j.urology.2014.03.019.

    Article  PubMed  Google Scholar 

  14. Tufan Tarcan NM, Ozay Ozgur M, Akbal C. OAB-V8 Aşırı Aktif Mesane Sorgulama Formu Validasyon Çalışması. Üroloji Bülteni. 2012;21:113–6.

    Google Scholar 

  15. Çentinel B, Özkan B, Can G. The validation study of ICIQ-SF Turkish version. 2004 30.

  16. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Philadelphia: Lawrence Erlbaum Associates; 1988.

    Google Scholar 

  17. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12 discussion 12.

    Article  PubMed  Google Scholar 

  18. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95. https://doi.org/10.1016/j.eururo.2012.10.016.

    Article  CAS  PubMed  Google Scholar 

  19. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. https://doi.org/10.1016/j.eururo.2012.10.048.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Health Sciences, Okmeydani Training & Research Hospital, 34098, Istanbul, Turkey

    Mehmet Gokhan Culha, Recep Burak Degirmentepe, Sait Ozbir & Suleyman Sami Cakir

  2. Japanese Red Cross Medical Center, Tokyo, Japan

    Yukio Homma

Authors
  1. Mehmet Gokhan Culha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Recep Burak Degirmentepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sait Ozbir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suleyman Sami Cakir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukio Homma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Gokhan Culha.

Ethics declarations

Conflict of interest

None.

The study was approved by the Institutional Review Board of Okmeydani Training and Research Hospital, and written informed consent was obtained from all participants.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 13 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Culha, M.G., Degirmentepe, R.B., Ozbir, S. et al. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. Int Urogynecol J 30, 2121–2126 (2019). https://doi.org/10.1007/s00192-019-04054-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-019-04054-0

Keywords

Search

Navigation